{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-gord/prescribing-information/h2-receptor-antagonists/","result":{"pageContext":{"chapter":{"id":"15ddfd64-70ae-5a0e-b1ca-6b8811278010","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists","depth":2,"htmlHeader":"<!-- begin field 195a4c17-80d2-48ae-a510-bd3135f6e1ed --><h2>H2-receptor antagonists</h2><!-- end field 195a4c17-80d2-48ae-a510-bd3135f6e1ed -->","summary":"","htmlStringContent":"<!-- begin item bcebfa4f-6d27-400c-adec-853a1abe9acb --><!-- end item bcebfa4f-6d27-400c-adec-853a1abe9acb -->","topic":{"id":"83831d3c-e98d-5e82-9fb9-cbd189e834d5","topicId":"8116d56b-de40-4191-af22-5152cc8f533c","topicName":"Dyspepsia - proven GORD","slug":"dyspepsia-proven-gord","lastRevised":"Last revised in April 2017","chapters":[{"id":"2b894900-36e2-56c8-9d00-aea95f9acd57","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"491fd89e-ec21-5541-b37c-3579bd40472f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6d91073e-8bb8-57e8-8ebf-c1b2832b3377","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69955f21-cf75-5568-9c39-b6894659d140","slug":"changes","fullItemName":"Changes"},{"id":"69e41821-9e9f-506e-bf29-9bb662d19fc5","slug":"update","fullItemName":"Update"}]},{"id":"a5332092-2e76-52c3-9c78-c55c73be1c36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ac987149-bd5e-543a-8025-d0a50c72b165","slug":"goals","fullItemName":"Goals"},{"id":"c282f1cd-c0cd-5cc2-b030-047fa174fc2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"35e91b3d-56f5-5130-8d0e-f0ad612196a3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fac73702-952e-57cf-a136-d52c4400cf78","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8add7bfe-1e06-5768-958d-3c09d529c285","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bb66df20-4142-59d4-913e-cf945ca4dacc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0449fde-d38f-58a1-aee2-098d0ab6ff60","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0a206efc-7aca-58e6-8462-5278f905b372","slug":"definition","fullItemName":"Definition"},{"id":"ce8c37c8-0936-52a2-87a7-0cbf130e1ce3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e1423a90-52a5-592c-ba4d-7f5a420ac54a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"cac2f410-0ab9-55d6-8bb8-acbe7735bd9c","slug":"complications","fullItemName":"Complications"},{"id":"9047f011-fcc3-521a-a802-30ac67c85c10","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a4a2f3e7-53b3-50ce-b717-6a6e8e5a219d","fullItemName":"Management","slug":"management","subChapters":[{"id":"6898f6b1-0345-5601-a084-c0f92474d0c9","slug":"dyspepsia-proven-gord","fullItemName":"Scenario: Dyspepsia - proven GORD"}]},{"id":"adea4c6d-b925-5d85-92be-9d322d882faf","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"bda71033-db69-5e58-977e-9d415fe4f646","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"15ddfd64-70ae-5a0e-b1ca-6b8811278010","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"}]},{"id":"dc717df5-19a4-5e7d-8391-be3e281ebdc8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"70508c23-67ec-5f56-b6cd-a9612c7e4e9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"713a3147-c4ed-5200-a0ab-51e195929400","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a10b2f69-154b-5dcc-8599-ae8de77e7eda","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6155a413-aefc-5575-b07c-111ad7697022","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f73cf98a-26ab-5f78-b8e4-d24d5a849283","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"94379789-e6c4-55fa-b460-965e551f4ea7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"64699d48-46e4-5ff1-97c0-8e280c75065c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"adea4c6d-b925-5d85-92be-9d322d882faf","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"fa4a087d-b35e-5a9c-a356-e29b2b6473e1","slug":"choice-of-h2-receptor-antagonist","fullItemName":"Choice of H2-receptor antagonist","depth":3,"htmlHeader":"<!-- begin field 6da3da98-26d5-42b1-a556-a335ba3149f3 --><h3>Choice of H2-receptor antagonist</h3><!-- end field 6da3da98-26d5-42b1-a556-a335ba3149f3 -->","summary":"","htmlStringContent":"<!-- begin item 6ac764d2-dd38-4caa-820f-afc51c382be4 --><!-- begin field 563e9a80-5982-469e-b7aa-07cc2af053a7 --><ul><li>Table 1 shows the recommended doses of ranitidine, famotidine, and nizatidine histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) for the management of people with gastro-oesophageal reflux disease (GORD).</li></ul><p><strong>Table 1</strong><strong>. </strong>Recommended doses of H<sub>2</sub>RAs for the management of people with GORD.</p><table><thead><tr><th colspan=\"1\"><p>H<sub>2</sub>RA</p></th><th colspan=\"1\"><p>Usual treatment dose</p></th><th colspan=\"1\"><p>Nocturnal dose (in addition to PPI)</p></th></tr></thead><tbody><tr><td colspan=\"1\">Ranitidine</td><td colspan=\"1\">150 mg twice a day</td><td colspan=\"1\">150 mg at night</td></tr><tr><td colspan=\"1\">Famotidine</td><td colspan=\"1\">20–40 mg twice a day</td><td colspan=\"1\">—</td></tr><tr><td colspan=\"1\">Nizatidine</td><td colspan=\"1\">150–300 mg twice a day</td><td colspan=\"1\">—</td></tr><tr><td colspan=\"3\">Note: cimetidine is also licensed for the treatment of GORD, however it is not recommended as there is a higher risk of drug interactions, due to inhibition of cytochrome P450 enzymes.</td></tr><tr><td colspan=\"3\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">BNF 72, 2016</a>]</td></tr></tbody></table><!-- end field 563e9a80-5982-469e-b7aa-07cc2af053a7 --><!-- end item 6ac764d2-dd38-4caa-820f-afc51c382be4 -->","subChapters":[]},{"id":"74c25d2c-d93b-554c-93ec-5ac4d7f0da8e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field dec98493-6ce0-4b85-b2c0-a7370177b948 --><h3>Contraindications and cautions</h3><!-- end field dec98493-6ce0-4b85-b2c0-a7370177b948 -->","summary":"","htmlStringContent":"<!-- begin item 15bdef1e-86c1-4129-a91a-a7370177b5cc --><!-- begin field 12ac389d-4013-42e3-b2b0-a7370177b948 --><ul><li><strong>Histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) should not be prescribed to people:</strong><ul><li>With alarm symptoms before endoscopy, as H<sub>2</sub>RAs may mask the symptoms of upper gastrointestinal malignancy. If the person is already taking an H<sub>2</sub>RA and subsequently needs an endoscopy, the H<sub>2</sub>RA should be stopped at least 2 weeks before the procedure.</li></ul></li><li><strong>H<sub>2</sub>RAs should be prescribed with caution in people with renal impairment:</strong><ul><li>For ranitidine, if the estimated glomerular filtration rate (eGFR) is less than 50 mL/minute/1.73m<sup>2</sup>, prescribe half the normal daily dose.</li><li>For famotidine, if the eGFR is less than 50 mL/minute/1.73m<sup>2</sup>, prescribe the normal dose once every 36–48 hours, or half the normal daily dose.</li><li>For nizatidine, if the eGFR is 20–50 mL/minute/1.73 m<sup>2</sup>, prescribe half the normal daily dose; if the eGFR is less than 20 mL/minute/1.73 m<sup>2</sup>, prescribe one-quarter of the normal daily dose.</li></ul></li><li><strong>Nizatidine should be prescribed with caution for people with hepatic impairment.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">BNF 72, 2016</a>]</p><!-- end field 12ac389d-4013-42e3-b2b0-a7370177b948 --><!-- end item 15bdef1e-86c1-4129-a91a-a7370177b5cc -->","subChapters":[]},{"id":"a465f438-d6c8-5675-a557-1519cb56a0d1","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 36b90cbd-82a3-4a75-be60-a736016f1992 --><h3>Adverse effects</h3><!-- end field 36b90cbd-82a3-4a75-be60-a736016f1992 -->","summary":"","htmlStringContent":"<!-- begin item 15147c9b-f9b4-41e2-834d-a736016f1351 --><!-- begin field 1483d589-e667-46f8-9a16-a736016f1992 --><ul><li>Adverse effects of histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) are uncommon and include diarrhoea, headache, dizziness, rash, and tiredness.</li><li>Rare or very rare adverse effects include hepatitis, cholestatic jaundice, bradycardia, depression, confusion, hallucinations, leucopenia, thrombocytopenia, and pancytopenia, arthralgia, and myalgia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">BNF 72, 2016</a>]</p><!-- end field 1483d589-e667-46f8-9a16-a736016f1992 --><!-- end item 15147c9b-f9b4-41e2-834d-a736016f1351 -->","subChapters":[]},{"id":"4711eb63-13d1-5613-92db-d4ee3a942c4d","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 012a5a6f-f121-4a95-bc6d-a736016f4b1f --><h3>Drug interactions</h3><!-- end field 012a5a6f-f121-4a95-bc6d-a736016f4b1f -->","summary":"","htmlStringContent":"<!-- begin item fac76e8a-e799-4f37-af0d-a736016f48df --><!-- begin field 467e1952-f8fc-42a1-9502-a736016f4b1f --><ul><li><strong>Possible drug interactions with histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) include:</strong><ul><li>Azole antifungals — because of decreased gastric acidity, the absorption of ketoconazole or itraconazole may be reduced if taken with an H<sub>2</sub>RA.</li><li>Protease inhibitors — atazanavir plasma levels are reduced by H<sub>2</sub>RAs. The manufacturer of atazanavir advises adjustment of the doses of both drugs when given with an H<sub>2</sub>RA. Seek specialist advice as needed.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">BNF 72, 2016</a>]</p><!-- end field 467e1952-f8fc-42a1-9502-a736016f4b1f --><!-- end item fac76e8a-e799-4f37-af0d-a736016f48df -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}